The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?REMDACTA 시험: 인터루킨 수용체 길항제가 COVID-19에서 추가적인 이점을 제공합니까? Published on 2021-11-012022-09-12 Journal: Intensive care medicine [키워드] antagonist benefit receptor [저자] Kate C Tatham, Manu Shankar-Hari, Yaseen M Arabi [Category] MERS, SARS, 진단, PMC URL [DOI] 10.1007/s00134-021-06540-w [Article Type] Editorial [Source] PMC All Keywords 【제목키워드】 receptor, antagonist, benefit,